Childhood acute lymphoblastic leukemia in the age of genomics

The recent sequencing of the human genome and technical breakthroughs now make it possible to simultaneously determine mRNA expression levels of almost all of the identified genes in the human genome. DNA “chip” or microarray technology holds great promise for the development of more refined, biologically‐based classification systems for childhood ALL, as well as the identification of new targets for novel therapy. To date gene expression profiles have been described that correlate with subtypes of ALL defined by morphology, immunophenotype, cytogenetic alterations, and response to therapy. Mechanistic insights into treatment failure have come from the definition of mRNA signatures that predict in vitro chemoresistance, as well as differences between blasts at relapse and new diagnosis. New bioinformatics tools optimize data mining, but validation of findings is essential since “over‐fitting” the data is a common danger. In the future, genomic analysis will be complemented by evaluation of the cancer proteome. © 2005 Wiley‐Liss, Inc.

[1]  Stephen M. Mount,et al.  The genome sequence of Drosophila melanogaster. , 2000, Science.

[2]  C. Echeverri,et al.  Oncology studies using siRNA libraries: the dawn of RNAi-based genomics , 2004, Oncogene.

[3]  Andrew Smith.  Genome sequence of the nematode C-elegans: A platform for investigating biology , 1998 .

[4]  X. Fu,et al.  Dysfunction of Stat4 leads to accelerated incidence of chemical-induced thymic lymphomas in mice. , 2001, Experimental and molecular pathology.

[5]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[6]  J. Berg.  Genome sequence of the nematode C. elegans: a platform for investigating biology. , 1998, Science.

[7]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[8]  Deborah A. Nickerson,et al.  Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans , 2003, Nature Genetics.

[9]  J. Radich,et al.  FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. , 2003, Blood.

[10]  Francis S. Collins,et al.  Genomic medicine--a primer. , 2002, The New England journal of medicine.

[11]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[12]  M. Schrappe,et al.  Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. , 2005, JAMA.

[13]  P. Whittaker,et al.  RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.

[14]  E. Petricoin,et al.  Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Rob Pieters,et al.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.

[16]  A. E. Sippel,et al.  Chromosomal localization of the four genes (NFIA, B, C, and X) for the human transcription factor nuclear factor I by FISH. , 1995, Genomics.

[17]  M. Relling,et al.  Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.

[18]  Aniko Szabo,et al.  Identification of gene expression profiles that segregate patients with childhood leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Dario Campana,et al.  FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. , 2005, Blood.

[20]  S. Perkins,et al.  Diversity of the apoptotic response to chemotherapy in childhood leukemia , 2002, Leukemia.

[21]  J. Welsh,et al.  Molecular classification of human carcinomas by use of gene expression signatures. , 2001, Cancer research.

[22]  T. Golub,et al.  Genomic approaches to hematologic malignancies. , 2004, Blood.

[23]  S. Perkins,et al.  Gene expression profiling reveals intrinsic differences between T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma , 2006, Pediatric blood & cancer.

[24]  P. Veys,et al.  Long‐term follow‐up of relapsed childhood acute lymphoblastic leukaemia , 2003, British journal of haematology.

[25]  M. Martineau,et al.  The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management , 2001, British journal of haematology.

[26]  W. Evans,et al.  Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia , 2000, Leukemia.

[27]  S. Armstrong,et al.  FLT3 mutations in childhood acute lymphoblastic leukemia. , 2004, Blood.

[28]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[29]  T. Taylor.  A group experience. , 1990, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[30]  E. J. Neves,et al.  Gene expression arrays in cancer research: methods and applications. , 2005, Critical reviews in oncology/hematology.

[31]  International Human Genome Sequencing Consortium.  Initial sequencing and analysis of the human genome , 2001, Nature.

[32]  E. Petricoin,et al.  Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. , 2003, Advances in experimental medicine and biology.

[33]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[34]  I. Bernstein,et al.  Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. , 2003, Blood.

[35]  F. Behm,et al.  Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia , 1998, Leukemia.

[36]  P. Steinherz,et al.  Survival after relapse in childhood acute lymphoblastic leukemia , 1998, Cancer.

[37]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[38]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[39]  Thomas Flohr,et al.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.

[40]  M. Relling,et al.  High incidence of secondary brain tumours after radiotherapy and antimetabolites , 1999, The Lancet.

[41]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[42]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1974, Nature.

[43]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[44]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.